177 related articles for article (PubMed ID: 37423332)
1. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
2. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
6. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
7. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract][Full Text] [Related]
9. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
10. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
11. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
13. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
15. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
[TBL] [Abstract][Full Text] [Related]
17. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
Handis C; Tanrıkulu B; Danyeli AE; Özek MM
Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
[TBL] [Abstract][Full Text] [Related]
18. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
[TBL] [Abstract][Full Text] [Related]
19. H3K27M Mutation Doesn't Mean Worse Prognosis in Old Patients.
Hu XM; Nie XY; Xu KL; Wang Y; Tang F; Du ZG; Xiong J
Front Oncol; 2022; 12():912166. PubMed ID: 35756637
[TBL] [Abstract][Full Text] [Related]
20. A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N; Poschke I; Lindner K; Bunse L; Mildenberger I; Boschert T; Jähne K; Green EW; Hülsmeyer I; Jünger S; Kessler T; Suwala AK; Eisele P; Breckwoldt MO; Vajkoczy P; Grauer OM; Herrlinger U; Tonn JC; Denk M; Sahm F; Bendszus M; von Deimling A; Winkler F; Wick W; Platten M; Sahm K
Nat Med; 2023 Oct; 29(10):2586-2592. PubMed ID: 37735561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]